{"ticker": {"uuid": "fbe47e86-35a8-4a10-b8db-314f5a7510e9", "symbol": "PHIO", "name": "Phio Pharmaceuticals Corp", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Phio Pharmaceuticals appoints dermatologist to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWWltTm55bDdxZHdISzhHM2xYMWQ5cW1jMFMtdnRLRzdKZ2NkWHhia0ZDN0Y1dzFoTF9FRHhXRmNyVFduR2RBaG1adEhJUlNSeGhPa1d4WjlWVkhVSnhSaVRoTjZadWJJNWhyc2s0d28yM05Mb0tZOEdianAxclNUQXUzYjE1VFFESlpZcjBwaWpDTk1uRTNWaUd4bXpsd2VpaG5OakVfSmxGNlR5d0RXZGhKbw?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-21T11:59:40+00:00", "published_display": "21 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee", "summary": "Phio Pharmaceuticals has announced the appointment of R. Todd Plott, M.D., to its Board of Directors, effective July 20, 2026. Dr. Plott will also serve as a member of the Governance Committee. He brings over 30 years of experience in dermatologic care and innovation, including a", "url": "https://www.tradingview.com/news/tradingview:220623b7bec4d:0-phio-pharmaceuticals-adds-r-todd-plott-to-its-board-joins-governance-committee/", "source_name": "TradingView", "published_at": "2026-07-21T11:39:47", "published_display": "21 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Than 30 Years in Dermatology: Phio Adds a Director", "summary": "Phio Pharmaceuticals has appointed Dr. R. Todd Plott, a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, to its Board of Directors. Dr. Plott's extensive background in dermatologic care, clinical research, drug development, ", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-appointment-of-dr-r-todd-plott-to-the-sjb60vptmlp0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:59:41", "published_display": "21 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors", "summary": "Phio Pharmaceuticals has appointed Dr. R. Todd Plott, an experienced dermatologist and researcher, to its Board of Directors. Dr. Plott brings over 30 years of experience in dermatologic care, clinical development, and as a former FDA advisory committee member, which will be a va", "url": "https://www.newsfilecorp.com/release/305879/Phio-Pharmaceuticals-Announces-Appointment-of-Dr.-R.-Todd-Plott-to-the-Board-of-Directors", "source_name": "TMX Newsfile", "published_at": "2026-07-21T10:39:47", "published_display": "21 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision", "summary": "Phio Pharmaceuticals has announced significant progress in protecting its proprietary INTASYL\u00ae gene silencing technology, securing multiple patent allowances and one grant in the United States, Canada, and Japan. These advancements strengthen the company's global intellectual pro", "url": "https://www.einpresswire.com/article/927385168/phio-pharmaceuticals-announces-patent-milestone-with-multiple-notices-of-allowance-and-grant-decision", "source_name": "EIN Presswire", "published_at": "2026-07-17T13:34:00", "published_display": "17 Jul 2026 13:34", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQN3k0dDZwNHNsVkpXU2o0RjZiSkwtVF9scXlRNmJQZUlPd21IaURMZVdFXzhTZTJwdTFpYWNxeGJBTklaSWFwS3lUR29iTGo4T3MyQlFWYWpwNzk5OUUxQ2x5a3ZMc3JBMWo3X1E0MmFUTzhmVE5iVVZ4MTY3bnd1bFkxczhWSS10M0RzRVY2OVdudDVxZE9vS20wQjRLQ29EempMSUJxZDIzbjFMUFJTR2Y5MTlPQWM4ZDM3RXUzb3BEWmVOaHc?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T12:59:38+00:00", "published_display": "15 Jul 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan", "summary": "Phio Pharmaceuticals (NASDAQ:PHIO) announced patent allowances and a grant decision in the U.S., Canada, and Japan for its INTASYL compounds, strengthening its intellectual property portfolio to 54 issued patents. The company's CEO emphasized the importance of strong patent prote", "url": "https://www.investing.com/news/company-news/phio-pharmaceuticals-receives-patent-allowances-in-us-canada-japan-93CH-4792960", "source_name": "Investing.com", "published_at": "2026-07-15T11:11:42", "published_display": "15 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals: 3 Patent Allowances, 1 Grant | PHIO Stock News", "summary": "Phio Pharmaceuticals (NASDAQ: PHIO) has announced significant progress in expanding its intellectual property for its INTASYL\u00ae gene silencing technology, receiving three patent notices of allowance and one grant decision across the United States, Canada, and Japan. These new pate", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-patent-milestone-with-multiple-88zc9n50ogan.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:11:42", "published_display": "15 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones", "summary": "Phio Pharmaceuticals has expanded its global intellectual property protection for its INTASYL\u00ae gene silencing platform with new patent milestones in the United States, Canada, and Japan. These additions bring the company's patent portfolio to 54 issued patents, covering various a", "url": "https://finance.yahoo.com/healthcare/articles/phio-pharmaceuticals-expands-global-patent-150650920.html", "source_name": "Market source", "published_at": "2026-07-15T11:06:00", "published_display": "15 Jul 2026 11:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. \u2013 NASDAQ:PHIO", "summary": "This page from TradingView provides financial information for Phio Pharmaceuticals Corp. under the NASDAQ:PHIO ticker. It focuses on the enterprise value to EBITDA forward metric for the company. The page also includes general market information, tools, and community links from t", "url": "https://www.tradingview.com/symbols/NASDAQ-PHIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:40:52", "published_display": "13 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Phio Pharmaceuticals Corp. \u2013 NASDAQ:PHIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPb0VCRlpyU1FhaFQ2QU9rcHNoYUEwUDFMVTZrRUt3QXFYd1pDSGxONHpYdFhpa0pPQUs5SllyYjZRZjBXWl82QnREc29ybnNQd3NuaFlINkRwdGc5R2xNLVVTMzZxeFI0eUFnMXkwS1NUMjFtckF5V096Tk4xQnFTbWJ2UklMUnk4UEIxQTZrbi03Rm1rUWxKVk80LTU?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T22:38:04+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO PE Ratio & Valuation, Is PHIO Overvalued", "summary": "This article analyzes the valuation of Phio Pharmaceuticals Corp (PHIO), noting it is currently in the \"Fair zone\" based on its forward PS ratio compared to its five-year average. It details current P/B ratios, Free Cash Flow yields, and compares PHIO's valuation metrics, such as", "url": "https://intellectia.ai/en/stock/PHIO/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-02T18:10:27", "published_display": "02 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series", "summary": "Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on June 30, 2026. CEO Robert Bitterman will present an overview of the company's INTASYL\u00ae siRNA platform, including its lead clinical candidate PH-762 for treating ", "url": "https://www.tradingview.com/news/tmx_newsfile:61e15e4ed094b:0-phio-pharmaceuticals-announces-participation-in-the-renmark-financial-communications-live-virtual-non-deal-roadshow-series/", "source_name": "TradingView", "published_at": "2026-06-30T18:42:15", "published_display": "30 Jun 2026 18:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com", "summary": "Phio Pharmaceuticals CEO Robert Bitterman recently purchased 10,000 shares of the company's common stock for a total of $9,900. This insider transaction occurred on June 26, 2026, with shares priced at $0.99 each. The stock is currently trading near its 52-week low, and an Invest", "url": "https://za.investing.com/news/stock-market-news/phio-pharmaceuticals-ceo-robert-bitterman-buys-9900-in-stock-93CH-4348476", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T04:10:17", "published_display": "30 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity", "summary": "Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, reported an open-market purchase of 10,000 shares of common stock at $0.99 per share on June 26, 2026. Following this transaction, Bitterman directly owns 421,421 shares, including those underlying un", "url": "https://www.stocktitan.net/sec-filings/PHIO/form-4-phio-pharmaceuticals-corp-insider-trading-activity-b89358847e08.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:40:58", "published_display": "30 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact", "summary": "Phio Pharmaceuticals Corp. (PHIO) announced strong safety and efficacy results for PH-762 in a phase I-B trial, leveraging their INTASYL platform. The company plans a new clinical trial next year and is actively seeking funding to expand indications, as highlighted in a recent fi", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3656681:0-phio-ph-762-achieved-strong-safety-and-efficacy-with-intasyl-poised-for-broader-clinical-impact/", "source_name": "TradingView", "published_at": "2026-06-29T18:10:40", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) chief adds 10,000 shares, now holds 421,421", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPc0NFVVdoUDhneHRrajhaRXZZdVppOTJyYzAzNnMycXBFMlpZNnlYRFFORHNja1g5WV9MNktZODMzWGlxNHZsQzk0TXlIWHVxSmpjYzU5N2NMMElOLUpHOG96d2t1bXFPSGk1bGRGbzNPQ2RaVkFRcFF1ZVVsbG5rOFl6Y3RNcjh2bHFBaVp2TTdVTno5YnpQM0ZaOGRfREwtNXFKT2poVVp1cTRDVHAtbFV0all1N0loeHdV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762", "summary": "Phio Pharmaceuticals has reached a significant milestone with the commencement of commercial-scale cGMP manufacturing of its lead candidate, PH-762, for its INTASYL\u00ae siRNA platform. This production, handled by Nitto Denko Avecia, Inc., follows the completion of Phio's Phase 1b do", "url": "https://www.einpresswire.com/article/922213425/phio-pharmaceuticals-reaches-key-milestone-in-advancing-lead-candidate-ph-762", "source_name": "EIN Presswire", "published_at": "2026-06-26T15:10:17", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio CEO to pitch INTASYL cancer platform in June 30 webcast", "summary": "Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow on June 30, 2026, where CEO Robert Bitterman will present the company's INTASYL siRNA platform and lead candidate PH-762 for skin cancers. PH-762 is an INTASYL compound th", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-participation-in-the-renmark-c0jxcaxfyfpo.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:10:03", "published_display": "26 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary", "summary": "Phio Pharmaceuticals provided a summary of their Life Sciences Virtual Investor Forum, highlighting their INTASYL platform which uses gene silencing to enhance immune cell effectiveness against cancer, specifically targeting cutaneous squamous cell carcinoma. Their PH-762 drug ca", "url": "https://quartr.com/events/phio-pharmaceuticals-corp-phio-life-sciences-virtual-investor-forum_FR772mIT", "source_name": "Quartr", "published_at": "2026-06-26T01:10:03", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Phio Pharmaceuticals Corp. (PHIO), including a price target of $14.00 from one analyst. It details the company's current stock performance, market capitalization, upcoming earnings date (August 6, 2026), and past financial results, highlightin", "url": "https://www.tradingview.com/symbols/NASDAQ-PHIO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:59", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1)", "summary": "This article provides an overview of Phio Pharmaceuticals Corp. (MUN:44R1) financial actuals, estimates, and analyst forecasts. It details historical stock performance, upcoming earnings reports, and key financial figures like EPS and revenue, noting that the company does not pay", "url": "https://www.tradingview.com/symbols/MUN-44R1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:03", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces \"How siRNA Therapy can Change the Course of Cancer Treatment\" in a Fireside Chat with Force Family Office on Monday, June 29, 2026", "summary": "Phio Pharmaceuticals is holding a virtual fireside chat on June 29, 2026, with Force Family Office to discuss how siRNA therapy can revolutionize cancer treatment. CEO Robert Bitterman and Dr. James Cardia will highlight their proprietary INTASYL\u00ae gene silencing technology, speci", "url": "https://www.newsfilecorp.com/release/302679/Phio-Pharmaceuticals-Announces-How-siRNA-Therapy-can-Change-the-Course-of-Cancer-Treatment-in-a-Fireside-Chat-with-Force-Family-Office-on-Monday-June-29-2026", "source_name": "TMX Newsfile", "published_at": "2026-06-25T10:40:08", "published_display": "25 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026", "summary": "Phio Pharmaceuticals will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO Robert Bitterman will present the company's INTASYL\u00ae siRNA platform and lead clinical candidate PH-762 for various skin cancers. The event will include a live presentation, Q&A sess", "url": "https://natlawreview.com/press-releases/phio-pharmaceuticals-announces-participation-life-sciences-investor-forum", "source_name": "The National Law Review", "published_at": "2026-06-24T13:40:08", "published_display": "24 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals begins commercial-scale production of PH-762", "summary": "Phio Pharmaceuticals has initiated commercial-scale cGMP production of its drug substance PH-762 at Nitto Denko Avecia, Inc. This marks a significant step towards the next phase of development for their lead clinical compound, PH-762, which is designed to silence the PD-1 gene fo", "url": "https://www.investing.com/news/company-news/phio-pharmaceuticals-begins-commercialscale-production-of-ph762-93CH-4757857", "source_name": "Investing.com", "published_at": "2026-06-24T12:12:09", "published_display": "24 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio\u2019s PH-762 clears a manufacturing step toward its next trial", "summary": "Phio Pharmaceuticals announced that Nitto Denko Avecia has begun commercial-scale cGMP production of PH-762 drug substance, a significant milestone for its lead candidate. This new supply is essential for supporting an upcoming clinical trial as Phio advances its intratumoral pro", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-reaches-key-milestone-in-advancing-lead-mdee9nmyu03r.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:10:09", "published_display": "24 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio CEO to pitch INTASYL cancer platform at investor forum June 25", "summary": "Phio Pharmaceuticals (NASDAQ: PHIO) CEO Robert Bitterman will present the company's INTASYL gene silencing technology and lead clinical candidate PH-762 for cutaneous carcinomas at the Life Sciences Investor Forum on June 25, 2026. The presentation will be followed by a live Q&A ", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-participation-in-the-life-sciences-fa5pfltslbbe.html", "source_name": "Stock Titan", "published_at": "2026-06-21T05:41:05", "published_display": "21 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phio Pharmaceuticals Announces \"Innovations in Skin Cancer Treatment and Prevention\" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phio-pharmaceuticals-announces-innovations-skin-110000798.html", "source_name": "TMX Newsfile", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOcHR4QzBRSHlqazBvZ0pMdHlkcElXeFNFNmN1cXUzZ2xrdFVDOE1VMHJsNmRCZnFsbHR4QWRsN1hOdWpsX0RFb2JxWTVzX2RiWV9VVXhjZ3lFNGZJV1BQZWxXQXNzWDVXc25qUjNkUnk3NXM1cFpsMGNIQy1Mb3pwR29QVkZXc3lDbUpJYS1rZHVNVFEzcllIZGFyd1M3OHg2LXNBZTBHbzlrZkJ2MzZXZWlMMk1wQ1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPb2w0cFkzUEswQWdvZEtfOGd3WFhsbXpCcVp5Rl9mOC1BYmRZSlhJUmFjNjVIc2dlOG16YzFQeFVCakJ3SmJKc3JZYk44VlliaEF0LWxlX0tCa0Nyb2tZZUhrSklPU2Rmd3FMYm16SDBTbUNCSzFzX2pQcm5MZUF1a3c0VmpSMFFrTzgxb0RMUG5hWEpsd01NQnNkN0lBbTNOZk44anhCaUVlSk5kR3lObTRCSUx4ck1rQzhiTllCX0I?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals stock soars after strong cancer treatment results", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOYnowUGhaZTg2bmRSVWhxNjJFZE1BWkVGbklMLXQ5VlRKTE81dDhxUmpxU3RCLWpCNmwxYy01RGFfamNrN3B1eF9TRmVkOVNDQTJLekJKS0VCVFBsVTFwWVJ5WlgybU1jNUJ6U3JfM0lxdFY0LUNoQkRFbUZnQzdsT0F5eGFzS1Z1QmdBZXVhajZ1YmRUWFUxOWhqbmhjTTZZM0NCWEdvMVVqeWRnaTdZUEp0UG11S0NNM1BzbWhKVGN2bXFKa2RNRUVQeXM?oc=5", "source_name": "Investing.com", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0tQW84LTJnOGozTVlYOExpMUxiX3JmWHA4WE0wNXVxaFRCTlZnUGhzQ2pabEQ2SC1tNmdWSU1kaG9PRkxzUDlhWmhPUTk3cURWVXVzSDA4UWZ5Zw?oc=5", "source_name": "MarketBeat", "published_at": "2019-03-28T06:34:51+00:00", "published_display": "28 Mar 2019 06:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Phio Pharmaceuticals appoints dermatologist to board By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOWWltTm55bDdxZHdISzhHM2xYMWQ5cW1jMFMtdnRLRzdKZ2NkWHhia0ZDN0Y1dzFoTF9FRHhXRmNyVFduR2RBaG1adEhJUlNSeGhPa1d4WjlWVkhVSnhSaVRoTjZadWJJNWhyc2s0d28yM05Mb0tZOEdianAxclNUQXUzYjE1VFFESlpZcjBwaWpDTk1uRTNWaUd4bXpsd2VpaG5OakVfSmxGNlR5d0RXZGhKbw?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-21T11:59:40+00:00", "published_display": "21 Jul 2026 11:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals adds R. Todd Plott to its Board, joins Governance Committee", "summary": "Phio Pharmaceuticals has announced the appointment of R. Todd Plott, M.D., to its Board of Directors, effective July 20, 2026. Dr. Plott will also serve as a member of the Governance Committee. He brings over 30 years of experience in dermatologic care and innovation, including a", "url": "https://www.tradingview.com/news/tradingview:220623b7bec4d:0-phio-pharmaceuticals-adds-r-todd-plott-to-its-board-joins-governance-committee/", "source_name": "TradingView", "published_at": "2026-07-21T11:39:47", "published_display": "21 Jul 2026 11:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "More Than 30 Years in Dermatology: Phio Adds a Director", "summary": "Phio Pharmaceuticals has appointed Dr. R. Todd Plott, a board-certified dermatologist and former FDA advisory committee member with over 30 years of experience, to its Board of Directors. Dr. Plott's extensive background in dermatologic care, clinical research, drug development, ", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-appointment-of-dr-r-todd-plott-to-the-sjb60vptmlp0.html", "source_name": "Stock Titan", "published_at": "2026-07-21T10:59:41", "published_display": "21 Jul 2026 10:59", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors", "summary": "Phio Pharmaceuticals has appointed Dr. R. Todd Plott, an experienced dermatologist and researcher, to its Board of Directors. Dr. Plott brings over 30 years of experience in dermatologic care, clinical development, and as a former FDA advisory committee member, which will be a va", "url": "https://www.newsfilecorp.com/release/305879/Phio-Pharmaceuticals-Announces-Appointment-of-Dr.-R.-Todd-Plott-to-the-Board-of-Directors", "source_name": "TMX Newsfile", "published_at": "2026-07-21T10:39:47", "published_display": "21 Jul 2026 10:39", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision", "summary": "Phio Pharmaceuticals has announced significant progress in protecting its proprietary INTASYL\u00ae gene silencing technology, securing multiple patent allowances and one grant in the United States, Canada, and Japan. These advancements strengthen the company's global intellectual pro", "url": "https://www.einpresswire.com/article/927385168/phio-pharmaceuticals-announces-patent-milestone-with-multiple-notices-of-allowance-and-grant-decision", "source_name": "EIN Presswire", "published_at": "2026-07-17T13:34:00", "published_display": "17 Jul 2026 13:34", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQN3k0dDZwNHNsVkpXU2o0RjZiSkwtVF9scXlRNmJQZUlPd21IaURMZVdFXzhTZTJwdTFpYWNxeGJBTklaSWFwS3lUR29iTGo4T3MyQlFWYWpwNzk5OUUxQ2x5a3ZMc3JBMWo3X1E0MmFUTzhmVE5iVVZ4MTY3bnd1bFkxczhWSS10M0RzRVY2OVdudDVxZE9vS20wQjRLQ29EempMSUJxZDIzbjFMUFJTR2Y5MTlPQWM4ZDM3RXUzb3BEWmVOaHc?oc=5", "source_name": "Investing.com South Africa", "published_at": "2026-07-15T12:59:38+00:00", "published_display": "15 Jul 2026 12:59", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals receives patent allowances in U.S., Canada, Japan", "summary": "Phio Pharmaceuticals (NASDAQ:PHIO) announced patent allowances and a grant decision in the U.S., Canada, and Japan for its INTASYL compounds, strengthening its intellectual property portfolio to 54 issued patents. The company's CEO emphasized the importance of strong patent prote", "url": "https://www.investing.com/news/company-news/phio-pharmaceuticals-receives-patent-allowances-in-us-canada-japan-93CH-4792960", "source_name": "Investing.com", "published_at": "2026-07-15T11:11:42", "published_display": "15 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals: 3 Patent Allowances, 1 Grant | PHIO Stock News", "summary": "Phio Pharmaceuticals (NASDAQ: PHIO) has announced significant progress in expanding its intellectual property for its INTASYL\u00ae gene silencing technology, receiving three patent notices of allowance and one grant decision across the United States, Canada, and Japan. These new pate", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-patent-milestone-with-multiple-88zc9n50ogan.html", "source_name": "Stock Titan", "published_at": "2026-07-15T11:11:42", "published_display": "15 Jul 2026 11:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Expands Global Patent Portfolio With New International Patent Milestones", "summary": "Phio Pharmaceuticals has expanded its global intellectual property protection for its INTASYL\u00ae gene silencing platform with new patent milestones in the United States, Canada, and Japan. These additions bring the company's patent portfolio to 54 issued patents, covering various a", "url": "https://finance.yahoo.com/healthcare/articles/phio-pharmaceuticals-expands-global-patent-150650920.html", "source_name": "Market source", "published_at": "2026-07-15T11:06:00", "published_display": "15 Jul 2026 11:06", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Phio Pharmaceuticals Corp. \u2013 NASDAQ:PHIO", "summary": "This page from TradingView provides financial information for Phio Pharmaceuticals Corp. under the NASDAQ:PHIO ticker. It focuses on the enterprise value to EBITDA forward metric for the company. The page also includes general market information, tools, and community links from t", "url": "https://www.tradingview.com/symbols/NASDAQ-PHIO/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-07-13T09:40:52", "published_display": "13 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Phio Pharmaceuticals Corp. \u2013 NASDAQ:PHIO", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxPb0VCRlpyU1FhaFQ2QU9rcHNoYUEwUDFMVTZrRUt3QXFYd1pDSGxONHpYdFhpa0pPQUs5SllyYjZRZjBXWl82QnREc29ybnNQd3NuaFlINkRwdGc5R2xNLVVTMzZxeFI0eUFnMXkwS1NUMjFtckF5V096Tk4xQnFTbWJ2UklMUnk4UEIxQTZrbi03Rm1rUWxKVk80LTU?oc=5", "source_name": "TradingView", "published_at": "2026-07-12T22:38:04+00:00", "published_display": "12 Jul 2026 22:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO PE Ratio & Valuation, Is PHIO Overvalued", "summary": "This article analyzes the valuation of Phio Pharmaceuticals Corp (PHIO), noting it is currently in the \"Fair zone\" based on its forward PS ratio compared to its five-year average. It details current P/B ratios, Free Cash Flow yields, and compares PHIO's valuation metrics, such as", "url": "https://intellectia.ai/en/stock/PHIO/valuation", "source_name": "Intellectia AI", "published_at": "2026-07-02T18:10:27", "published_display": "02 Jul 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series", "summary": "Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series on June 30, 2026. CEO Robert Bitterman will present an overview of the company's INTASYL\u00ae siRNA platform, including its lead clinical candidate PH-762 for treating ", "url": "https://www.tradingview.com/news/tmx_newsfile:61e15e4ed094b:0-phio-pharmaceuticals-announces-participation-in-the-renmark-financial-communications-live-virtual-non-deal-roadshow-series/", "source_name": "TradingView", "published_at": "2026-06-30T18:42:15", "published_display": "30 Jun 2026 18:42", "sentiment": "positive", "sentiment_pct": 64, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals CEO Robert Bitterman buys $9,900 in stock By Investing.com", "summary": "Phio Pharmaceuticals CEO Robert Bitterman recently purchased 10,000 shares of the company's common stock for a total of $9,900. This insider transaction occurred on June 26, 2026, with shares priced at $0.99 each. The stock is currently trading near its 52-week low, and an Invest", "url": "https://za.investing.com/news/stock-market-news/phio-pharmaceuticals-ceo-robert-bitterman-buys-9900-in-stock-93CH-4348476", "source_name": "Investing.com South Africa", "published_at": "2026-06-30T04:10:17", "published_display": "30 Jun 2026 04:10", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4] Phio Pharmaceuticals Corp. Insider Trading Activity", "summary": "Phio Pharmaceuticals Corp.'s Chairman, President, and CEO, Robert J. Bitterman, reported an open-market purchase of 10,000 shares of common stock at $0.99 per share on June 26, 2026. Following this transaction, Bitterman directly owns 421,421 shares, including those underlying un", "url": "https://www.stocktitan.net/sec-filings/PHIO/form-4-phio-pharmaceuticals-corp-insider-trading-activity-b89358847e08.html", "source_name": "Stock Titan", "published_at": "2026-06-30T03:40:58", "published_display": "30 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO: PH-762 achieved strong safety and efficacy, with INTASYL poised for broader clinical impact", "summary": "Phio Pharmaceuticals Corp. (PHIO) announced strong safety and efficacy results for PH-762 in a phase I-B trial, leveraging their INTASYL platform. The company plans a new clinical trial next year and is actively seeking funding to expand indications, as highlighted in a recent fi", "url": "https://www.tradingview.com/news/urn:summary_document_transcript:quartr.com:3656681:0-phio-ph-762-achieved-strong-safety-and-efficacy-with-intasyl-poised-for-broader-clinical-impact/", "source_name": "TradingView", "published_at": "2026-06-29T18:10:40", "published_display": "29 Jun 2026 18:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) chief adds 10,000 shares, now holds 421,421", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxPc0NFVVdoUDhneHRrajhaRXZZdVppOTJyYzAzNnMycXBFMlpZNnlYRFFORHNja1g5WV9MNktZODMzWGlxNHZsQzk0TXlIWHVxSmpjYzU5N2NMMElOLUpHOG96d2t1bXFPSGk1bGRGbzNPQ2RaVkFRcFF1ZVVsbG5rOFl6Y3RNcjh2bHFBaVp2TTdVTno5YnpQM0ZaOGRfREwtNXFKT2poVVp1cTRDVHAtbFV0all1N0loeHdV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762", "summary": "Phio Pharmaceuticals has reached a significant milestone with the commencement of commercial-scale cGMP manufacturing of its lead candidate, PH-762, for its INTASYL\u00ae siRNA platform. This production, handled by Nitto Denko Avecia, Inc., follows the completion of Phio's Phase 1b do", "url": "https://www.einpresswire.com/article/922213425/phio-pharmaceuticals-reaches-key-milestone-in-advancing-lead-candidate-ph-762", "source_name": "EIN Presswire", "published_at": "2026-06-26T15:10:17", "published_display": "26 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio CEO to pitch INTASYL cancer platform in June 30 webcast", "summary": "Phio Pharmaceuticals will participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow on June 30, 2026, where CEO Robert Bitterman will present the company's INTASYL siRNA platform and lead candidate PH-762 for skin cancers. PH-762 is an INTASYL compound th", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-participation-in-the-renmark-c0jxcaxfyfpo.html", "source_name": "Stock Titan", "published_at": "2026-06-26T11:10:03", "published_display": "26 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) Life Sciences Virtual Investor Forum Summary", "summary": "Phio Pharmaceuticals provided a summary of their Life Sciences Virtual Investor Forum, highlighting their INTASYL platform which uses gene silencing to enhance immune cell effectiveness against cancer, specifically targeting cutaneous squamous cell carcinoma. Their PH-762 drug ca", "url": "https://quartr.com/events/phio-pharmaceuticals-corp-phio-life-sciences-virtual-investor-forum_FR772mIT", "source_name": "Quartr", "published_at": "2026-06-26T01:10:03", "published_display": "26 Jun 2026 01:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PHIO Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Phio Pharmaceuticals Corp. (PHIO), including a price target of $14.00 from one analyst. It details the company's current stock performance, market capitalization, upcoming earnings date (August 6, 2026), and past financial results, highlightin", "url": "https://www.tradingview.com/symbols/NASDAQ-PHIO/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T18:40:59", "published_display": "25 Jun 2026 18:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Corp. Actuals & Estimates (MUN:44R1)", "summary": "This article provides an overview of Phio Pharmaceuticals Corp. (MUN:44R1) financial actuals, estimates, and analyst forecasts. It details historical stock performance, upcoming earnings reports, and key financial figures like EPS and revenue, noting that the company does not pay", "url": "https://www.tradingview.com/symbols/MUN-44R1/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T18:10:03", "published_display": "25 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces \"How siRNA Therapy can Change the Course of Cancer Treatment\" in a Fireside Chat with Force Family Office on Monday, June 29, 2026", "summary": "Phio Pharmaceuticals is holding a virtual fireside chat on June 29, 2026, with Force Family Office to discuss how siRNA therapy can revolutionize cancer treatment. CEO Robert Bitterman and Dr. James Cardia will highlight their proprietary INTASYL\u00ae gene silencing technology, speci", "url": "https://www.newsfilecorp.com/release/302679/Phio-Pharmaceuticals-Announces-How-siRNA-Therapy-can-Change-the-Course-of-Cancer-Treatment-in-a-Fireside-Chat-with-Force-Family-Office-on-Monday-June-29-2026", "source_name": "TMX Newsfile", "published_at": "2026-06-25T10:40:08", "published_display": "25 Jun 2026 10:40", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026", "summary": "Phio Pharmaceuticals will participate in the Life Sciences Investor Forum on June 24-25, 2026. CEO Robert Bitterman will present the company's INTASYL\u00ae siRNA platform and lead clinical candidate PH-762 for various skin cancers. The event will include a live presentation, Q&A sess", "url": "https://natlawreview.com/press-releases/phio-pharmaceuticals-announces-participation-life-sciences-investor-forum", "source_name": "The National Law Review", "published_at": "2026-06-24T13:40:08", "published_display": "24 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals begins commercial-scale production of PH-762", "summary": "Phio Pharmaceuticals has initiated commercial-scale cGMP production of its drug substance PH-762 at Nitto Denko Avecia, Inc. This marks a significant step towards the next phase of development for their lead clinical compound, PH-762, which is designed to silence the PD-1 gene fo", "url": "https://www.investing.com/news/company-news/phio-pharmaceuticals-begins-commercialscale-production-of-ph762-93CH-4757857", "source_name": "Investing.com", "published_at": "2026-06-24T12:12:09", "published_display": "24 Jun 2026 12:12", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio\u2019s PH-762 clears a manufacturing step toward its next trial", "summary": "Phio Pharmaceuticals announced that Nitto Denko Avecia has begun commercial-scale cGMP production of PH-762 drug substance, a significant milestone for its lead candidate. This new supply is essential for supporting an upcoming clinical trial as Phio advances its intratumoral pro", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-reaches-key-milestone-in-advancing-lead-mdee9nmyu03r.html", "source_name": "Stock Titan", "published_at": "2026-06-24T11:10:09", "published_display": "24 Jun 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio CEO to pitch INTASYL cancer platform at investor forum June 25", "summary": "Phio Pharmaceuticals (NASDAQ: PHIO) CEO Robert Bitterman will present the company's INTASYL gene silencing technology and lead clinical candidate PH-762 for cutaneous carcinomas at the Life Sciences Investor Forum on June 25, 2026. The presentation will be followed by a live Q&A ", "url": "https://www.stocktitan.net/news/PHIO/phio-pharmaceuticals-announces-participation-in-the-life-sciences-fa5pfltslbbe.html", "source_name": "Stock Titan", "published_at": "2026-06-21T05:41:05", "published_display": "21 Jun 2026 05:41", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Announces \"Innovations in Skin Cancer Treatment and Prevention\" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/phio-pharmaceuticals-announces-innovations-skin-110000798.html", "source_name": "TMX Newsfile", "published_at": "2026-05-12T11:00:00+00:00", "published_display": "12 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio CEO heads to Nasdaq Marketsite for April 14 investor presentation", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOcHR4QzBRSHlqazBvZ0pMdHlkcElXeFNFNmN1cXUzZ2xrdFVDOE1VMHJsNmRCZnFsbHR4QWRsN1hOdWpsX0RFb2JxWTVzX2RiWV9VVXhjZ3lFNGZJV1BQZWxXQXNzWDVXc25qUjNkUnk3NXM1cFpsMGNIQy1Mb3pwR29QVkZXc3lDbUpJYS1rZHVNVFEzcllIZGFyd1M3OHg2LXNBZTBHbzlrZkJ2MzZXZWlMMk1wQ1U?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-09T07:00:00+00:00", "published_display": "09 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxPb2w0cFkzUEswQWdvZEtfOGd3WFhsbXpCcVp5Rl9mOC1BYmRZSlhJUmFjNjVIc2dlOG16YzFQeFVCakJ3SmJKc3JZYk44VlliaEF0LWxlX0tCa0Nyb2tZZUhrSklPU2Rmd3FMYm16SDBTbUNCSzFzX2pQcm5MZUF1a3c0VmpSMFFrTzgxb0RMUG5hWEpsd01NQnNkN0lBbTNOZk44anhCaUVlSk5kR3lObTRCSUx4ck1rQzhiTllCX0I?oc=5", "source_name": "TMX Newsfile", "published_at": "2026-03-05T08:00:00+00:00", "published_display": "05 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals stock soars after strong cancer treatment results", "summary": "", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxOYnowUGhaZTg2bmRSVWhxNjJFZE1BWkVGbklMLXQ5VlRKTE81dDhxUmpxU3RCLWpCNmwxYy01RGFfamNrN3B1eF9TRmVkOVNDQTJLekJKS0VCVFBsVTFwWVJ5WlgybU1jNUJ6U3JfM0lxdFY0LUNoQkRFbUZnQzdsT0F5eGFzS1Z1QmdBZXVhajZ1YmRUWFUxOWhqbmhjTTZZM0NCWEdvMVVqeWRnaTdZUEp0UG11S0NNM1BzbWhKVGN2bXFKa2RNRUVQeXM?oc=5", "source_name": "Investing.com", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTE0tQW84LTJnOGozTVlYOExpMUxiX3JmWHA4WE0wNXVxaFRCTlZnUGhzQ2pabEQ2SC1tNmdWSU1kaG9PRkxzUDlhWmhPUTk3cURWVXVzSDA4UWZ5Zw?oc=5", "source_name": "MarketBeat", "published_at": "2019-03-28T06:34:51+00:00", "published_display": "28 Mar 2019 06:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 83, "total_relevant": 41, "sentiment_summary": {"positive": 21, "negative": 1, "neutral": 19, "score": 62, "total": 41, "label": "Constructive news tone", "tone": "positive"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 13.75, "count": 25}, {"event": "earnings", "label": "Earnings", "weight": 6.46, "count": 14}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}, {"event": "macro", "label": "Macro sensitivity", "weight": 0.55, "count": 1}], "positive_events": 21, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 1.03, "latest_week": "2026-07-17", "one_week_move": 1.0, "four_week_move": 0.0, "twelve_week_move": -13.4, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.457289, "market_dynamics_buy_signal": false, "relative_strength": -37.412773, "fair_value_gap": -77.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 40.2324, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "+1.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "News confirmed by price", "tone": "positive", "classification": "confirmed_positive", "summary": "Constructive news tone is being confirmed by positive weekly price action.", "confidence": 73, "badges": ["Sentiment-trend disagreement", "Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": ["Positive news is arriving while the Sharemaestro trend signal is inactive."], "event_label": "Market update", "sentiment_word": "constructive"}, "charts": {"sources": [{"label": "TradingView", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "Market source", "count": 7}, {"label": "TMX Newsfile", "count": 4}, {"label": "Investing.com South Africa", "count": 3}, {"label": "Investing.com", "count": 3}, {"label": "EIN Presswire", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 32}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 25}, {"label": "Earnings", "count": 14}, {"label": "Balance sheet", "count": 1}, {"label": "Macro sensitivity", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "62/100", "tone": "positive", "text": "Constructive news tone"}, {"label": "Market reaction", "value": "News confirmed by price", "tone": "positive", "text": "Constructive news tone is being confirmed by positive weekly price action."}, {"label": "Primary event", "value": "Market update", "tone": "positive", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "32", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+1.0% over one week, +0.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Phio Pharmaceuticals appoints dermatologist to board By Investing.com"}], "updated_at": "2026-07-22T08:40:43.116995+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}